Gain Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Gain Therapeutics

08/05/2024 15:05

* Gain Therapeutics Inc  GANX.OQ   GANX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 10
(estimated) for the period ending March 31 2024
    * The Bethesda Maryland-based  company is expected to report
a
45.5% decrease in revenue to $30 thousand from $55 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Gain Therapeutics Inc is
for a
loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gain
Therapeutics
Inc is $9.00​, above​ its last closing price of $2.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.30       -0.32      -0.36     Missed  -11.6
 Sep. 30 0001  -0.45       -0.45      -0.37     Beat    17
 Jun. 30 2023  -0.32       -0.31      -0.62     Missed  -101.6
                                                        ​
 Jan. 1 0001   -0.40       -0.39      -0.43     Missed  -9.3
 ​​Dec.        -0.38       -0.38      -0.39     Missed  -3.3
 31 2022                                                
 Sep. 30 2022  -0.46       -0.46      -0.38     Beat    17.4​
 Jun. 30 2022  -0.31       -0.31      -0.43     Missed  -37.2
 Mar. 31 2022  -0.37       -0.37      -0.28     Beat    23.8
 This summary was machine generated May 8 at 14:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)